| |
|
|
|
| Research
Profile - D. Gordon Allan, MD |
|
|
|
|
| Department/Division: |
|
|
Email
Address: |
| Surgery/Orthopaedics |
gallan@siumed.edu |
| Office
Location: |
|
|
Location
of Laboratory: |
| 800
N. Rutledge, room 219 Springfield |
|
911
N. Rutledge, room 330 |
| Office
Phone Number: |
|
|
Laboratory
Phone Number: |
| 217-545-8865 |
|
|
217-545-7780 |
| Willing
to mentor medical students and / or residents?
|
Yes |
| Research
Interests: |
Adult
lower extremity reconstructive surgery, including osteochondral,
large segment, and soft tissue allograft surgery, revision
arthroplasty surgery.
Musculoskeletal oncology.
DVT prophylaxis after total joint replacement.
Undergraduate and postgraduate medical education.
Wear of orthopaedic implants, including systemic release
of wear debris.
Development of novel nanocoatings to reduce in vivo
wear of orthopaedic implants. |
| Techniques
and Methodologies: |
Clinical follow-up research.
Trace metal analysis using high resolution ICP-mass
spectrometry, cell culture, immunohistochemistry, ELISA,
standard molecular biology techniques. |
|
Equipment:
|
Thermocycler,
gel electrophoresis equipment, shaker incubator, cell
culture biohood and incubator, -80 degree freezer, sonicator |
Current
Collaborators:
|
Rita
Trammell, PhD
Peter Filip, PhD
Manish Paliwal, PhD
Candice Bearss, clinical trials coordinator
Michelle Dufour, clinical trials coordinator |
| Current
and Pending Awards: |
D.
Gordon Allan, PI:
VerSys Hip System Clinical Study Protocol. Zimmer,
2/97 to present
NexGen Complete Knee Solution Clinical Study Protocol.
Zimmer, 2/97 to present
Prospective Randomized Multicenter Study of NexGen
LPS-Flex Knee. Zimmer, Inc., 9/01 to present
Unicompartmental Knee Arthroplasty Prospective Multi-Center
Clinical Outcome Study. Zimmer Inc., 5/2002 to present
Non-Randomized, Safety and Efficacy Study of the Cormet
2000 Metal On Metal Resurfacing Hip System ˆ
An FDA Investigational Device Study. Corin, USA, 9/01
to present
Acumatch M-Series ˆ Exactech Integrated Hip System.
Exactech, Inc., 3/00 to present
OP-1 Implant. Stryker Biotech, 3/03 to present
Pending:
A Multi-Center, Double-Blind, Placebo-Controlled,
Randomized Study of the Analgesic Efficacy and Safety
of Valdecoxib 20mgqd and Valdecoxib 20mgbid Compared
to Placebo Over Multiple Days for Management of Acute
Post-Surgical Pain in Patients Undergoing Anterior
Cruciate Ligament Reconstruction (Protocol: A3471109).
Pfizer Inc., Approved 4/22/4
Co-Investigator: David J. Olysav, M.D., Rodney J.
Herrin, M.D., Diane Hillard-Sembell, M.D.
A Phase 2 Randomized, Double-Blind (BMS-562247 and
enoxaparin)
Active-Controlled (enoxaparin and warfarin), Parallel-
Arm, Dose-Response Study of the Oral Factor Xa Inhibitor
BMS-562247 in Subjects Undergoing Elective Total Knee
Replacement Surgery. Bristol-Myers Squibb Company,
Co-Investigator: David J. Olysav, M.D.
A Randomized, Parallel-Group, Double-Blind, Active
Controlled Study to Investigate the Efficacy and Safety
of Two Different Dose Regimens of Dabigatran Administered
Orally Compared to Enoxaparin Subcutaneous, in Prevention
of Venous Thromboembolism in Patients with primary
Elective Total Knee Replacement Surgery. Boehringer
Ingelheim Pharmaceuticals, Inc.
Evaluation of the new generation of modular total
hip prostheses, Memorial Medical Center Foundation,
9/1/2004-8/31/2005 |
| Publications:
|
|
|
|
1.
Chilvers M, Vejvoda H, Trammell R, et al.: Trochanteric
fixation in total hip arthroplasty using the S-ROM
bolt and washer. J Arthroplasty 17:740, 2002
2. Allan DG, Trammell R: The role of arthroscopy in
the evaluation and management of the problematic total
knee arthroplasty. Indian Journal of Orthopaedics
36:80, 2002
3. Trammell, R.; Johnson, C.; Barker, J.; Bell, R.;
Allan, D.G.: "MDR-1 Gene Expression Does Not
Increase During Tumor Progression in the MGH-OGS Murine
Osteosarcoma Tumor Model," Journal of Orthopaedic
Research, Vol. 18 (3), 2000; 449-455.
4. Powers, L.; Trammell, R.; L‚Hommedieu, C.;
Allan, D.G.: "MDR-1 Gene Expression in Human
Soft Tissue Sarcomas: Relation to Clinical Outcome."
The Journal of Bone and Joint Surgery Orthopaedic
Proceedings, Supplement I, Vol. 81-B: 100. 1999.
5. Trammell, R.; Powers, L.; Jewett, T.; Allan, D.G.:
"Expression of Multidrug-Resistance-Associated
Protein (MRP) in Adult Soft Tissue Sarcomas: Relation
to Clinical Outcome." Mid-America Orthopaedic
Association, (submitted).
6. Caronis, G.; Trammell, R.; Allan, D.G.: "The
Effect of HBO and GM-CSF on Wound Healing Variables
and TGF-B1 Levels in Doxorubicin Compromised Wounds."
Orthopaedic Transactions, Vol. 22(2):478. 1998-1999
7. Trammell, R.; Johnson, C.; Barker, J.; Allan, D.G.:
"Expression of the Multidrug Resistance Gene
in a Murine Osteogenic Sarcoma Tumour Model during
Tumour Progression". Orthopaedic Transactions,
Vol 22(2): 476. 1998-1999 |
Optional-CV
Web address:
|
|
| |
|
|
| |
|
|
|
|
|
|
|
